Patients with lymphoma involvement in the GI tract had significantly decreased PIM1 (9.1 vs. 25.0%, P = 0.034) and MYD88 (0 vs. 20.8%, P = 0.001) mutations than those without GI tract involvement. Here, MYD88 is linked to lymphoma.